Exagen Inc. to Participate in Third Quarter Investor Conferences

Exagen Inc. (Nasdaq: XGN), a prominent player in the field of autoimmune diagnostics, has announced its participation in two significant investor conferences in August and September 2025. The company will engage in both a fireside chat and one-on-one meetings at the Canaccord Genuity 45th Annual Growth Conference, scheduled for August 12, 2025, at the InterContinental Hotel in Boston, MA. Following this, Exagen will participate in the Cantor Global Healthcare Conference 2025 on September 3, 2025, at the Marriott Marquis Hotel in New York, NY.

Headquartered in Carlsbad, California, Exagen is dedicated to enhancing the diagnosis and management of chronic autoimmune diseases through its advanced testing solutions. The company’s flagship product, AVISE® CTD, offers clinicians vital support in diagnosing complex conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease with improved accuracy and speed. Exagen’s specialized laboratory provides a comprehensive suite of AVISE-branded tests designed for disease diagnosis, prognosis, and monitoring, ultimately aimed at improving clinical outcomes for patients.

Exagen’s commitment to innovation, research, and patient-centered care sets it apart in the competitive landscape of autoimmune disease management. The company's ongoing focus on addressing the challenges faced by patients and healthcare providers alike has positioned it as a meaningful contributor in the realm of autoimmune diagnostics. For further updates and information, Exagen encourages stakeholders to visit its website or follow the company on social media platforms.

For any investor-related inquiries, Ryan Douglas from Exagen’s investor relations can be reached at ir@exagen.com or via phone at 760.560.1525.

Exagen Inc. (Nasdaq: XGN) is poised for significant growth in the autoimmune diagnostics sector and presents a compelling investment opportunity, especially in light of its scheduled participation in notable investor conferences this September. The company specializes in providing advanced testing for chronic autoimmune diseases, with its flagship AVISE® CTD test designed to enhance diagnosis and treatment of conditions like lupus and rheumatoid arthritis.

As Exagen participates in the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, and the Cantor Global Healthcare Conference on September 3, investor interest is likely to heighten. These conferences provide a platform for Exagen to showcase its innovative testing solutions and strategic direction, potentially attracting new investors and solidifying relationships with existing ones.

The ongoing demand for precise diagnostics in autoimmune diseases is driven by increasing prevalence rates and the need for early intervention. Exagen's commitment to research, innovation, and patient-centered care aligns well with current healthcare trends, making it a strong candidate for both short- and long-term investment. Its comprehensive suite of AVISE-branded tests not only positions it as a market leader but also reinforces its commitment to clinical excellence and improved patient outcomes, a significant selling point for healthcare investors.

From a financial perspective, potential investors should closely monitor Exagen's performance post-conferences as announcements related to partnerships, research developments, or clinical trial results could significantly impact stock valuation. Additionally, keep an eye on the competitive landscape within the diagnostics market, as advancements in technology and regulatory changes can influence market dynamics.

In conclusion, Exagen Inc. is strategically positioned for growth and stands out as an attractive investment opportunity in the evolving healthcare sector, particularly for those focused on innovative companies in the diagnostics field. Investors should consider these upcoming events as pivotal moments for potential market movements.